Format

Send to

Choose Destination
Bull Cancer. 2011 Oct;98(9):80-9. doi: 10.1684/bdc.2011.1436.

Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.

Author information

1
CHU Hautepierre, Department of Oncology & Hematology, Strasbourg, France. irene.asmane@wanadoo.fr

Abstract

OBJECTIVES:

As vascular endothelial growth factor (VEGF) is expressed in ovarian cancer, we assessed the efficacy and safety of bevacizumab (a monoclonal antibody targeting VEGF) plus microtubule targeting agents for heavily pre-treated ovarian carcinoma patients.

METHODS:

We retrospectively reviewed 43 patients with recurrent epithelial ovarian carcinoma. Combined treatment included bevacizumab with paclitaxel in 32 (74%), docetaxel in 10 (23%), and vinorelbine in one (2.3%) patients, respectively.

RESULTS:

The median number of combined treatment was six cycles (range 1-29). On RECIST criteria, the objective response rate (ORR) was 40% (16% CR and 24% PR). Clinical benefit (complete response [CR] plus partial response [PR] and stable disease [SD] lasting ≥ 3 months) was 74% (CI95%: 46.7-77%). Median duration of treatment and overall survival were 3.9 months (range 0.2-14.4 months) and 20.1 months (CI95%: 13.8-20.1) respectively. No toxic death was reported. Grade 3-4 toxicity occurred in 30% of patients. Gastrointestinal perforations and fistula occurred in 3 (7%) and 6 (14%) patients, respectively.

CONCLUSION:

Although being active in terms of ORR, bevacizumab plus microtubule targeting agents - mainly taxanes - leads to a high rate of gastro-intestinal perforations and fistula in heavily pre-treated ovarian carcinoma patients.

PMID:
21926034
DOI:
10.1684/bdc.2011.1436
[Indexed for MEDLINE]
Free full text

MeSH terms, Substances, Supplementary concept

Supplemental Content

Full text links

Icon for John Libbey Eurotext
Loading ...
Support Center